Ricardo Ferreira
Head of Flow Cytometry Facility
I have a long-standing interest in understanding the regulation of the human immune system and the mechanisms underlying disease development. I am particularly interested in developing and implementing single-cell technologies — ranging from multiparametric flow cytometry to single-cell multi-omics — to dissect the heterogeneity of the human immune system.
During my nine years of postdoctoral research at the University of Oxford in the Todd-Wicker lab, I developed advanced cellular immunophenotyping approaches to investigate the impact of immunotherapy on the human T-cell compartment in the context of autoimmune disease. Since 2025, I have been leading the new consolidated NDM Flow Cytometry Facility in the Old Road Campus (ORC), where I provide essential flow cytometry support and expertise for researchers across a broad range of projects.
In this role, I oversee the operation, development, and long-term sustainability of the facility, including user training, technology implementation, and strategic development. I am passionate about teaching and supporting both new and experienced researchers across diverse applications. We also actively engage in collaborative projects and are interested in developing new funding opportunities for research initiatives and instrument acquisition.
At the ORC Flow Cytometry Facility, we work closely with researchers from experimental design and sample preparation through to data analysis, enabling the generation of high-quality, reproducible data.
Recent publications
Hiding in Plain Sight: CD8+FOXP3+Tregs sequester CD25 and are enriched in human tissues
Preprint
Jarvis LB. et al, (2023)
SARS-CoV-2 infection induces a long-lived pro-inflammatory transcriptional profile
Journal article
Zhang J-Y. et al, (2023), Genome Medicine, 15
Neutrophils and emergency granulopoiesis drive immune suppression and an extreme response endotype during sepsis
Journal article
Kwok AJ. et al, (2023), Nature Immunology, 24, 767 - 779
CD56bright natural killer cells preferentially kill proliferating CD4+ T cells
Journal article
Lee M. et al, (2023), Discovery Immunology, 2
Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes
Journal article
Zhang J-Y. et al, (2022), Nature Communications, 13